90734-71-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(6-CHLOROIMIDAZO[1,2-B]PYRIDAZIN-3-YL)-ETHANONE is used as a key intermediate in the synthesis of pyridazine-based compounds for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. Its unique chemical structure allows for the development of novel therapeutic agents that can potentially alleviate the symptoms and slow the progression of these debilitating conditions.
In the synthesis process, 1-(6-CHLOROIMIDAZO[1,2-B]PYRIDAZIN-3-YL)-ETHANONE serves as a building block for the creation of more complex molecules with specific biological activities. Its presence in the molecular structure of the final product is crucial for the compound's ability to interact with target proteins and pathways implicated in neurodegeneration, thereby offering a promising avenue for the development of new therapeutic agents.
Furthermore, the use of 1-(6-CHLOROIMIDAZO[1,2-B]PYRIDAZIN-3-YL)-ETHANONE in pharmaceutical research and development highlights the importance of chemical reagents in the advancement of medicine. As researchers continue to explore its potential applications and optimize its synthesis, 1-(6-CHLOROIMIDAZO[1,2-B]PYRIDAZIN-3-YL)-ETHANONE may contribute to the discovery of innovative treatments for a range of neurodegenerative disorders, ultimately improving the quality of life for affected individuals.

InChI:InChI=1/C8H6ClN3O/c1-5(13)6-4-10-8-3-2-7(9)11-12(6)8/h2-4H,1H3

Upstream product

• 598-31-2 1-bromoacetone 
• 35053-55-5 N'-(6-chloropyridazin-3-yl)-N,N-dimethylmethanimidamide 
• 78-95-5 chloroacetone 

Downstream Products

• 453547-85-8 (4-imidazo[1,2-b]pyridazin-3-yl-pyrimidin-2-yl)-phenyl-amine 
• 1264837-95-7 (rac)-4-{3-[1-(5,7-difluoro-quinolin-6-yl)-ethyl]-imidazo[1,2-b]pyridazin-6-yl}-1-phenylpiperazin-2-one 
• 453548-65-7 1-(imidazo[1,2-b]pyridazin-3-yl)ethanone 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS

The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

A novel benzoyl amide compounds

The invention relates to the field of medicinal chemistry, in particular to a novel benzamides compound or a salt acceptable in parmacy of the novel benzamides compound, a preparation method of the novel benzamides compound, a pharmaceutical composition containing the novel benzamides compound and an application of the pharmaceutical composition in preparation of antineoplastic drugs.

A 2-amino-thiazole compounds (by machine translation)

The present invention relates to the technical field of pharmaceutical chemistry, particularly relates to a 2-amino thiazole compound or its pharmaceutically acceptable salts, its preparation method, and pharmaceutical compositions containing such compounds and its application in the preparation of antineoplastic. (by machine translation)

HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION

The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

HETEROCYCLIC OXIME COMPOUNDS

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Imidazo[1,2-b]pyridazines: A potent and selective class of cyclin-dependent kinase inhibitors

Modification of imidazo[1,2-a]pyridine CDK inhibitors lead to identification of less lipophilic imidazo[1,2-b]pyridazine series of CDK inhibitors. Although several equivalent compounds from these two series have similar structure and show similar CDK acti